CDK4 and breast cancer: Finally, given that CDKN2A mutations have been linked to a worse prognosis and a high likelihood of malignant progression, CDK4/6 inhibitors, which are currently used in breast cancer and have been studied in glioblastoma, can also be of interest in the treatment of patients with IDH-mutant gliomas.